An observational study in Nasopharyngeal Carcinoma by AJCC V8 Stage and Radiation Induced Mucositis, sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Mucositis with a site in China — 5 open to participants now, 5 under way, none of them phase 3. Mucositis · China.
Among the 10 studies in Mucositis with a site in China, this one is the only one that started in 2022, is one of 2 observational ones, and was the 6th registered.
265 studies on the registry are indexed under Mucositis; 34 are open to participants now.
Browse Mucositis studies →5 of the 10 studies in Mucositis with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18–65
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in China
Ages 18+ · Healthy volunteers
The General Hospital of Western Theater Command · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 90 across 34 observational studies indexed under Mucositis.
Median enrollment 99 across the 8 interventional studies, 360 across the 2 observational. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University is the lead sponsor of 28 studies on the registry; 15 are open to participants now.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University has 1 study filed under Mucositis — fewer than ten, so there is no comparison to draw.
1 of the studies in Mucositis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400328The First Affiliated Hospital of Soochow UniversityAmimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Mucositis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Exploring effective risk prediction models for severe Radiation-Induced Oral Mucositis (RIOM/RTOM), providing a research basis for mitigating oral radiation toxicity, and effectively improving the sensitivity of dentists in predicting the risk of severe RIOM in locally advanced nasopharyngeal carcinoma patients.Based on precise radiotherapy, it is proposed to extract OAR using the contour of local oral areas. Explore more accurate RIOM dose-response relationships.Exploring a new type of fusion classifier, by complementing the information between each base classifier, helps to maximize the utilization of the information contained in different factors to build a more objective, reliable, and efficient multi criteria decision-making based risk prediction model for severe RIOM. It use predictive models to identify key risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive mode.
This study investigates the prediction and management of Radiation-Induced Oral Mucositis (RIOM/RTOM) in patients with locally advanced nasopharyngeal carcinoma undergoing radiotherapy. RIOM is a significant concern due to its impact on the quality of life for patients and its potential to disrupt radiotherapy courses, affecting local tumor control rates. We systematically analyzed multifaceted data, including dosimetric parameters, clinical factors, and oral variables, to develop a predictive model for severe RIOM. The effectiveness of key risk factors in mitigating the risk of severe RIOM was further validated to predict and potentially prevent severe RIOM.
Nasopharyngeal cancer patients diagnosed with tissue biopsy and no distant metastasis, who underwent RTOM observation and treatment throughout the radiotherapy period in the Department of Stomatology
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group aims to develop an artificial intelligence model using a retrospective cohort to predict severe RIOM in patients diagnosed with LA-NPC and evaluate risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive model.The oral evaluation of all patients was conducted by the same senior dentist, who evaluated the oral mucosal radiation toxicity weekly at baseline (before RT) and after RT, and performed RIOM scores.RIOM is classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0) .
Other: Intervention based on key factors identified by the severe RIOM prediction model
Intervention based on key factors identified by the severe RIOM prediction model
Incidence of severe RIOM
According to the CTCAE V5.0 ,Grade 3 and Grade 4 is considered severe RTOM
Time frame: during radiotherapy
Risk factors of severe RIOM
Patient factors, disease factors, and treatment related factors
Time frame: baseline (before radiotherapy)
Changes from oral dryness in RIOM patients
According to the Clinical oral dryness score(CODS),A total of 10 features were used to obtain the total CODS. A high total score indicates increased oral dryness.
Time frame: Baseline, the 10th, 20th and 30th days of radiotherapy
Changes from salivary PH compared to baseline in RIOM patients
Evaluation of salivary PH using pH indicator paper
Time frame: Baseline, the 10th, 20th and 30th days of radiotherapy
Changes from the pain in xerostomia combined with RIOM patients
The evaluation of pain is based on the Numerical Rating Scale (NRS), with a numerical score of 0-10. A score of less than 5 is considered mild pain, a score of 5-7 is moderate pain, and a score of 8 or above is severe pain.
Time frame: Baseline, the 10th, 20th and 30th days of radiotherapy
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jun 2024, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University